Mlaignant histiocytosis. Results of combination vincristine-prednisone therapy.
D000293:Adolescent; D000368:Aged; D001856:Bone Marrow Examination; D001859:Bone Neoplasms / Q000188:drug therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D006471:Gastrointestinal Hemorrhage / Q000401:mortality; D006644:Histiocytes; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy* / Q000473:pathology; D008099:Liver / Q000201:enzymology; D008113:Liver Neoplasms / Q000188:drug therapy; D008198:Lymph Nodes / Q000473:pathology; D008207:Lymphatic Metastasis / Q000473:pathology; D008297:Male; D011241:Prednisone / Q000627:therapeutic use*; D011517:Prothrombin Time; D013160:Splenic Neoplasms / Q000188:drug therapy; D014750:Vincristine / Q000627:therapeutic use*
D014750:Vincristine; D003520:Cyclophosphamide; D011241:Prednisone